Search results for "Perl"

showing 10 items of 383 documents

Management of Dyslipidemia in the Metabolic Syndrome

2007

In order to characterize the metabolic syndrome it becomes necessary to establish a number of diagnostic criteria. Because of its impact on cardiovascular morbidity/mortality, considerable attention has been focussed on the dyslipidemia accompanying the metabolic syndrome. The aim of this review is to highlight the fundamental aspects of the pathophysiology, diagnosis, and the treatment of the metabolic syndrome dyslipidemia with recommendations to clinicians. The clinical expression of the metabolic syndrome dyslipidemia is characterized by hypertriglyceridemia and low levels of high-density lipoprotein-cholesterol (HDL-C). In addition, metabolic syndrome dyslipidemia is associated with hi…

medicine.medical_specialtyBioinformaticsClofibric Acidchemistry.chemical_compoundInsulin resistanceInternal medicineHyperlipidemiamedicineHumansPharmacology (medical)DyslipidemiasMetabolic Syndromemedicine.diagnostic_testCholesterolbusiness.industryCholesterol HDLHypertriglyceridemianutritional and metabolic diseasesGeneral Medicinemedicine.diseaseEndocrinologyPostprandialchemistrySpainPractice Guidelines as Topiclipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsMetabolic syndromeCardiology and Cardiovascular MedicineLipid profilebusinessDyslipidemiaAmerican Journal of Cardiovascular Drugs
researchProduct

A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin

2013

Ghrelin is a peptide hormone produced mainly in the stomach that has widespread tissue distribution and diverse hormonal, metabolic and cardiovascular activities. The circulating ghrelin concentration increases during fasting and decreases after food intake. Ghrelin secretion may thus be initiated by food intake and is possibly controlled by nutritional factors. Lean subjects have increased levels of circulating ghrelin compared with obese subjects. Recent reports show that low plasma ghrelin is associated with elevated fasting insulin levels, insulin resistance and type 2 diabetes mellitus. Factors involved in the regulation of ghrelin secretion have not yet been defined; however, it is as…

medicine.medical_specialtyCardiotonic AgentsHyperlipidemias030209 endocrinology & metabolismPeptide hormoneBiologyCardiovascular System03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusInsulin SecretionDrug DiscoverymedicineAnimalsHumansHypoglycemic AgentsInsulinAntiatherogenic agentHypolipidemic Agents030304 developmental biology2. Zero hungerPharmacology0303 health sciencesEvidence-Based Medicinedigestive oral and skin physiologyType 2 Diabetes MellitusLipid Metabolismmedicine.diseaseGhrelin3. Good healthEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesGastric MucosaHyperglycemiaGhrelinhormones hormone substitutes and hormone antagonistsGhrelin secretionHormoneCurrent Pharmaceutical Design
researchProduct

Hypolipidaemic effects of fenofibrate and fasting in the herbivorous grass carp (Ctenopharyngodon idella) fed a high-fat diet

2008

We investigated whether the hypolipidaemic effect of fenofibrate and fasting observed in most omnivorous mammals may also apply to herbivorous fish. Grass carp (Ctenopharyngodon idella) fed a high-fat (8 %) diet exhibited a marked increase in blood lipids and body fat after 6 weeks. They were then treated with fenofibrate (100 mg/kg body weight) in the same high-fat diet for 2 weeks, followed by fasting for 1 week. Plasma lipid concentration, body fat amount, fatty acid composition, plasma thiobarbituric acid-reactive substances and some parameters related to hepatic fatty acid oxidation were measured, and liver samples were stained for histological examination. Fenofibrate treatment decrea…

medicine.medical_specialtyCarpsmedicine.drug_classMedicine (miscellaneous)Blood lipidsHyperlipidemiasFibrateBiologyThiobarbituric Acid Reactive SubstancesLipid peroxidationFish Diseaseschemistry.chemical_compoundFenofibrateInternal medicinemedicineAnimalsBeta oxidationHypolipidemic AgentsNutrition and DieteticsFenofibrateCholesterolFatty AcidsLipid metabolismFastingLipid Metabolismbiology.organism_classificationCombined Modality TherapyDietary FatsGrass carpEndocrinologyLiverchemistryAnimal Nutritional Physiological Phenomenalipids (amino acids peptides and proteins)Lipid PeroxidationOxidation-Reductionmedicine.drugBritish Journal of Nutrition
researchProduct

Hyperlipidemia Prevalence and Cholesterol Control in OSA: Data from European Sleep Apnea Database (ESADA)

2019

European-Respiratory-Society (ERS) International Congress -- SEP 28-OCT 02, 2019 -- Madrid, SPAIN

medicine.medical_specialtyCholesterolbusiness.industryConfoundingnutritional and metabolic diseasesSleep apneaDiseasemedicine.diseasenervous system diseasesrespiratory tract diseasesObstructive sleep apneachemistry.chemical_compoundstomatognathic systemchemistryInternal medicineCohortHyperlipidemiamedicineIn patientbusinessHypoxia
researchProduct

Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review

2020

Background: Dyslipidemia is the main factor involved in the occurrence and progression of coronary artery disease. Objective: The research strategy is aimed at analyzing new data on the pathophysiology of dyslipidemia involvement in coronary artery disease, the modalities of atherogenic risk estimation and therapeutic advances. Method: Scientific articles published in PubMed from January 2017 to February 2018 were searched using the terms "dyslipidemia" and "ischemic heart disease". Results: PCSK9 contributes to the increase in serum levels of low-density lipoprotein-cholesterol and lipoprotein (a). The inflammation is involved in the progression of hyperlipidemia and atherosclerosis. Hype…

medicine.medical_specialtyFamilial hypercholesterolemiaDiseaseCoronary Artery Disease030204 cardiovascular system & hematologyArticlestatinsCoronary artery disease03 medical and health sciences0302 clinical medicineproprotein convertase subtilisin/kexin type 9Risk FactorsInternal medicineHyperlipidemiamedicineHumans030212 general & internal medicinetriglyceridesCoronary atherosclerosisDyslipidemiasbusiness.industryPCSK9dyslipidemiaGeneral Medicinemedicine.diseaseCholesterolCardiologyArterial stiffnessCardiology and Cardiovascular MedicinebusinessDyslipidemiaCurrent Cardiology Reviews
researchProduct

How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks fo…

2020

Familial hypercholesterolemia (FH) is a common genetic disorder of lipid metabolism, still underdiagnosed and undertreated in the general population. Pathology registers could play a crucial role in the creation of a comprehensive and integrated global approach to cover all aspects of this disease. Systematic data collection of patients affected by FH has increased dramatically worldwide in the past few years. Moreover, results from registers already established for the longest time showed their potentialities in the implementation of the knowledge of FH, comparing country-specific approaches and providing real-world data about identification, management and treatment of FH individuals in t…

medicine.medical_specialtyGenotypeFamilial hypercholesterolemiaPopulationFamilial hypercholesterolemiaDisease030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineGenetic dyslipidaemiasFamilial hypercholesterolemia; Genetic dyslipidaemias; Pathology registersInternal MedicineHumansMedicineGenetic Predisposition to DiseaseRegistries030212 general & internal medicineeducationIntensive care medicineHypolipidemic Agentseducation.field_of_studybusiness.industryGenetic disorderDiagnostic algorithmsGeneral MedicinePathology registersmedicine.diseaseClinical PracticePhenotypeItalyCardiovascular DiseasesHeart Disease Risk FactorsDisease riskIdentification (biology)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessAlgorithmsAtherosclerosis Supplements
researchProduct

Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?

2019

Abstract Background Although lipid-lowering drugs, especially statins, and recently also PCSK9 inhibitors can reduce LDL cholesterol (LDL-C) and decrease the risk for cardiovascular disease (CVD) including coronary artery disease (CAD) events most efficiently, only 5–10% of high-risk cardiovascular patients reach the target values recommended by international guidelines. In patients who cannot be treated adequately by drugs it is possible to reduce increased LDL-C and/or lipoprotein(a) (Lp(a)) values by the use of lipoprotein apheresis (LA) with the potential to decrease severe CVD events in the range of 70%->80%. Even in Germany, a country with well-established reimbursement guidelines for…

medicine.medical_specialtyHyperlipoproteinemiasReferralPopulationDisease030204 cardiovascular system & hematologyRisk AssessmentHealth Services AccessibilityCoronary artery disease03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal MedicinemedicineHumans030212 general & internal medicineIntensive care medicineeducationCompetence (human resources)Reimbursementeducation.field_of_studybusiness.industryPatient SelectionGeneral MedicineCholesterol LDLmedicine.diseaseCardiovascular DiseasesBlood Component RemovalPatient ComplianceLipid loweringCardiology and Cardiovascular MedicinebusinessLipoprotein apheresisBiomarkersLipoprotein(a)Atherosclerosis. Supplements
researchProduct

Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multice…

2015

Lipoprotein apheresis (LA) can lower LDL-cholesterol and Lp(a) by 60%-70% and is the final escalating option in patients with hyperlipoproteinemias involving LDL or Lp(a) particles. Major therapeutic effect of LA is preventing cardiovascular events. In Germany since 2008 a reimbursement guideline has been implemented accepting to establish the indication for LA not only for familial or severe forms of hypercholesterolemia but also based on Lp(a)-hyperlipoproteinemia associated with a progressive course of cardiovascular disease, that persists despite effective treatment of other concomitant cardiovascular risk factors. The Pro(a)LiFe-study confirmed with a prospective multicenter design tha…

medicine.medical_specialtyHyperlipoproteinemiasTime FactorsDiseaseRisk AssessmentCoronary artery diseasePredictive Value of TestsRisk FactorsInternal medicineMulticenter trialGermanyInternal MedicinemedicineHumansProspective StudiesFamily historyRetrospective Studiesbiologybusiness.industryTherapeutic effectGeneral MedicineGuidelineLipoprotein(a)medicine.diseaseSurgeryTreatment OutcomeCardiovascular Diseasesbiology.proteinCardiologyBlood Component RemovalDisease ProgressionCardiology and Cardiovascular MedicineRisk assessmentbusinessBiomarkersLipoprotein(a)Atherosclerosis. Supplements
researchProduct

Does adiponectin play a role in the pathogenesis of chronic spontaneous urticaria?

2020

Introduction Chronic spontaneous urticaria constitutes an interdisciplinary problem and its pathogenesis is still a subject of debate. Overweight and hyperlipidemia are supposed to be related to chronic spontaneous urticaria. Fatty tissue can be the source of adipokines. Aim of the study To assess the potential role of adiponectin in chronic spontaneous urticaria pathogenesis. Material and methods The study included 52 chronic spontaneous urticaria patients and 43 healthy controls. The patients were divided into two subgroups: patients with wheals only, and patients with urticaria and an accompanying angioedema. The adiponectin concentration was measured in all studied subjects. Results No …

medicine.medical_specialtyImmunologylcsh:MedicineAdipose tissueAdipokineOverweightGastroenterologychronic urticariaPathogenesisimmune system diseasesInternal medicineHyperlipidemiaparasitic diseasesmedicineImmunology and Allergyskin and connective tissue diseasesadipokinesAdiponectinAngioedemaadiponectinbusiness.industrypathogenesislcsh:RSignificant differencemedicine.diseaseClinical Immunologymedicine.symptombusinessmetabolismCentral-European Journal of Immunology
researchProduct

Plasma derived protein C in severe sepsis: report of two cases

2008

Severe sepsis is defined as sepsis-associated organ dysfunction, (arterial hypoxemia, acute oliguria, coagulation abnormalities, thrombocytopenia, hyperbilirubinemia), hypoperfusion (hyperlactatemia) and arterial hypotension (mean arterial pressure \70 mmHg, or a systolic blood pressure decrease[40 mmHg) [3, 4]. Septic shock [3, 4] is defined as acute circulatory failure induced by sepsis with hypotension despite adequate fluid resuscitation. A dysfunction of the protein C (PC) pathway is always present in severe sepsis and contributes to the development of coagulopathy and necrosis [12, 13]. This decrease is caused by consumption of protein C during systemic activation of blood coagulation…

medicine.medical_specialtyMean arterial pressurebusiness.industrySeptic shockOrgan dysfunctionProteolytic enzymesmedicine.diseaseGastroenterologySepsisPlasmaInternal medicineEmergency MedicineInternal MedicinemedicineHyperlactatemiamedicine.symptombusinessProtein Cmedicine.drugPurpura fulminansInternal and Emergency Medicine
researchProduct